Business
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical S...
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate
About this update from Sight Sciences, Inc.
[{"type":"text","content":"Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology \n Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted through 24 monthsConfirmed safety and efficacy of OMNI Surgical System technology in both standalone and combination cataract proceduresLongest published multicenter clinical results of OMNI Surgical System to date MENLO PARK, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the publication of two-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the OMNI® Surgical System technology to date in both standalone and combination-cataract surgery demonstrated that the significant reductions in IOP and medication usage observed at 12 months were also witnessed at 24 months. In addition, there were no serious or unanticipated adverse events during the length of the two-year study. \"This longer-term data set representing patients treated at multiple centers throughout the country both at the time of cataract surgery and as a standalone treatment should give eye surgeons even greater confidence about the safety and durability of efficacy of the OMNI Surgical System technology,\" said Blake Williamson, MD, of The Williamson Eye Center in Baton Rouge, LA, and a principal investigator of the study. \"Knowing that OMNI maintains effectiveness through two-years, and beyond, is very reassuring, not only to me, but also to my patients.\" Sites participating in this extension study accounted for 86 percent of eyes enrolled in the original ROMEO study from seven multi-specialty ophthalmology practices in six states (Arkansas, California, Kansas, Louisiana, Missouri, and New York). Patients with mild-moderate glaucoma ...